MolNFT v1 · #110676 · protein
Endothiapepsin in complex with fragment 207
4Y3T: “Endothiapepsin in complex with fragment 207”. X-ray diffraction, 2 ligands (46H, 46J), 2 pockets (best druggability 0.58). MolNFT v1 #110676 on GenesisL1: 3D structure, binding sites and pockets in GL1X.
- PDB
- 4Y3T
- Type
- protein
- Length
- 330 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Endothiapepsin
- EC
- 3.4.23.22
- UniProt
- P11838
- Ligands
- 46H, 46J
- Pockets
- 2 · best druggability 0.58
Structure
x-ray diffraction · 1 distinct chain · 11% helix, 45% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Endothiapepsin (EC 3.4.23.22) | protein | 330 | 11% helix, 45% strand | P11838 |
Ligands and binding sites
- 46H · (3S)-piperidin-3-yl(piperidin-1-yl)methanone · ligand · 2 copies · chains A
- 46J · (3R)-piperidin-3-yl(piperidin-1-yl)methanone · ligand · chains A
- GOL · Glycerol · additive · 6 copies · chains A
- DMS · Dimethyl sulfoxide · additive · 6 copies · chains A
- ACT · Acetate ion · additive · 3 copies · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 321 | 0.58 | 0.76 | 38 | DMS, 46J, 46H |
| 2 | 50 | 0.30 | 0.77 | 14 | empty |
Modifications
Observed in the structure: 1 disulfide (disulfide).
Compared structures
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt P11838
- Elsewhere: RCSB PDB 4Y3T · PDBe 4Y3T · UniProt P11838
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.